- Home
- OSTX vs KALA Comparison
OSTX vs KALA Comparison
Compare OSTX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- KALA
- Stock Information
- Founded
- OSTX 2018
- KALA 2009
- Country
- OSTX United States
- KALA United States
- Employees
- OSTX N/A
- KALA N/A
- Industry
- OSTX
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- KALA Health Care
- Exchange
- OSTX NYSE
- KALA Nasdaq
- Market Cap
- OSTX 45.0M
- KALA 26.2M
- IPO Year
- OSTX 2024
- KALA 2017
- Fundamental
- Price
- OSTX $1.53
- KALA $3.72
- Analyst Decision
- OSTX Strong Buy
- KALA Strong Buy
- Analyst Count
- OSTX 3
- KALA 2
- Target Price
- OSTX $18.00
- KALA $13.50
- AVG Volume (30 Days)
- OSTX 345.0K
- KALA 56.4K
- Earning Date
- OSTX 05-16-2025
- KALA 05-14-2025
- Dividend Yield
- OSTX N/A
- KALA N/A
- EPS Growth
- OSTX N/A
- KALA N/A
- EPS
- OSTX N/A
- KALA N/A
- Revenue
- OSTX N/A
- KALA N/A
- Revenue This Year
- OSTX N/A
- KALA N/A
- Revenue Next Year
- OSTX N/A
- KALA N/A
- P/E Ratio
- OSTX N/A
- KALA N/A
- Revenue Growth
- OSTX N/A
- KALA N/A
- 52 Week Low
- OSTX $1.12
- KALA $2.92
- 52 Week High
- OSTX $7.00
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- KALA 46.95
- Support Level
- OSTX N/A
- KALA $3.67
- Resistance Level
- OSTX N/A
- KALA $4.16
- Average True Range (ATR)
- OSTX 0.00
- KALA 0.31
- MACD
- OSTX 0.00
- KALA 0.08
- Stochastic Oscillator
- OSTX 0.00
- KALA 53.89
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.